Status:
UNKNOWN
Target Effect-site Concentration of Remifentanil in Transperineal Prostate Puncture
Lead Sponsor:
Chinese Medical Association
Conditions:
Anesthesia, Intravenous
Eligibility:
MALE
18+ years
Brief Summary
The research about the target effect-site concentration of remifentanil, inhibiting stress reaction of the perineal prostate puncture when Dexmedetomidine being continuous pumping
Detailed Description
Patients who were scheduled to undergo transperineal prostate puncture and biopsy were recruited into our study. In all patients, dexmedetomidine was injected at a bolus of 0.6 mg/kg and then continuo...
Eligibility Criteria
Inclusion
- patients of perineal prostate puncture
Exclusion
- sinus bradycardia or atrioventricular block serious heart, brain, lung, liver, kidney, and metabolic disease allergy for dexmedetomidine or opioid
Key Trial Info
Start Date :
January 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2018
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT03428191
Start Date
January 1 2017
End Date
February 1 2018
Last Update
February 9 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Changhai Hospital
Shanghai, Shanghai Municipality, China, 200433